$17.30
-0.25-1.42%
Last update: Nov 10, 6:35 PM
Omeros Corp
OMERNASDAQ
Omeros rose 151.1% from $6.89 to $17.30, ahead of the S&P 500's +9.8%. Its worst day was Jun 26 (−19.1%), and its low came Nov 13 at $6.28.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.34 beat the $-0.52 estimate on $0.00 revenue (est. $312,500.00).
+25.3% · S&P 500 0.0%
Omeros shares rose 75.5%, while the S&P 500 rose 0.4%.
Story events cover the past 12 months · Times ET
+75.5%, the year's best day, on 25M shares, the year's heaviest volume · S&P 500 +0.4%
EPS of $3.14 beat the $-0.01 estimate on $0.00 revenue (est. $1.6M).
+14.4% · S&P 500 +0.8%
EPS of $-0.24 beat the $-0.30 estimate on $9.9M revenue (est. $10.1M).
−7.6% · S&P 500 +0.8%
Omeros Corporation (NASDAQ:OMER) announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company’s marketing authorization
−19.1%, the year's worst day · S&P 500 −0.7%
EPS of $0.02 beat the $-0.32 estimate on $28.5M revenue (est. $12.6M).
+26.5% · S&P 500 +0.7%
Omeros closed at its highest level of the year, 205.5% above where the year started.
+13.8% · S&P 500 0.0%
Where it ended: a close of $17.30 on Nov 10, 2026. Up next: Q3 2026 earnings on Nov 16, 2026 (EPS est. $-0.03, revenue est. $36.0M).
Nothing in the past 12 months.
All OMER dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for OMER and SPY from Benzinga historical bars. Not investment advice.
